Myla Lai-Goldman MD

venture Partner

Dr. Myla Lai-Goldman has over 30 years’ experience in the development, commercialization and adoption of novel molecular diagnostic assays. In 2011, with Drs. Chuck Perou and Neil Hayes of the University of North Carolina at Chapel Hill, she co-founded GeneCentric Therapeutics, a Hatteras Fund III company leveraging deep RNA expertise to develop and commercialize both tissue and blood based diagnostics for precision cancer care. Both the PurIST assay, launched in collaboration with Tempus, Inc to guide 1st-line PDAC therapy, and GenomicsNext™, allowing us to infer gene expression directly from standard circulating tumor DNA (ctDNA) sequencing, are examples of GeneCentric’s recent accomplishments. 

Until her retirement on December 31, 2008, Myla was Executive Vice President, Chief Medical Officer of Laboratory Corporation of America® Holdings (LabCorp®), where she managed LabCorp’s National Office of Quality and Science, through which she was responsible for all quality, science and medical activities for LabCorp and its subsidiaries. From 1998 until April 2008, Myla also served as Chief Scientific Officer of the company, where she was responsible for R & D. Until 2006, she managed the operations of the Company’s Center for Molecular Biology and Pathology in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; and ViroMed Laboratories, Inc. in Minneapolis, MN. Additionally, she held the position of Medical Director for the Center for Molecular Biology and Pathology from 1991 to 2005. Myla joined the Company in 1990.

Myla is the Managing Partner of Personalized Science, LLC, a clinical diagnostics consulting firm she founded in 2008.  

Myla earned an MD from the College of Physicians and Surgeons at Columbia University in New York, and completed postgraduate training in Internal Medicine at St Luke’s Hospital in New York, anatomic and clinical pathology at the UCLA Center for Health Sciences, and hematopathology at the University of North Carolina at Chapel Hill. She is board-certified in anatomic and clinical pathology.

COMMUNITY AND BOARD ENGAGEMENTS:
Myla serves as the Chairperson for GeneCentric Therapeutics and a board member for West Pharmaceutical Services, Quanterix Corporation, Mercy Bioanalytics, and NovoPath. She also serves on the Scientific Advisory Board of Hitachi High-Tech America.